Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?

In the era of targeted therapy and a multitude of agents to manage anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (aNSCLC), optimal treatment sequencing to achieve the best patient outcomes is yet to be elucidated. Relevant contemporary randomised trials compare single lines of treatment head-to-head but are not designed to investigate this important question.